Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease

$2,432,649R44FY2024AGNIH

Virogenics, Inc., Del Mar CA

Investigators

William C Raschkecontact Pamela Anne Maher

View original record on NIH RePORTER →